Conduit Pharmaceuticals Inc.
CDT
$0.9101
-$0.1599-14.94%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.65M | 2.32M | 3.12M | 2.83M | 2.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.78M | 5.41M | 3.14M | 2.96M | 2.43M |
| Operating Income | -4.78M | -5.41M | -3.14M | -2.96M | -2.43M |
| Income Before Tax | -2.41M | -6.46M | -5.38M | -3.55M | 245.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.41M | -6.46M | -5.38M | -3.55M | 245.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.41M | -6.46M | -5.38M | -3.55M | 245.00K |
| EBIT | -4.78M | -5.41M | -3.14M | -2.96M | -2.43M |
| EBITDA | -4.33M | -5.41M | -- | -- | -- |
| EPS Basic | -2.15 | -7.41 | -7.29 | -4.81 | 0.33 |
| Normalized Basic EPS | -1.88 | -4.06 | -4.56 | -3.01 | 0.21 |
| EPS Diluted | -2.15 | -7.41 | -7.29 | -5.00 | -3.66 |
| Normalized Diluted EPS | -1.88 | -4.06 | -4.56 | -3.01 | 0.20 |
| Average Basic Shares Outstanding | 1.12M | 871.60K | 738.50K | 738.30K | 732.20K |
| Average Diluted Shares Outstanding | 1.12M | 871.60K | 738.50K | 738.30K | 751.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
